Angiographic evidence of coronary artery disease in at least one major epicardial vessel on screening CCTA.
History of myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or coronary revascularization by percutaneous coronary intervention.
You may not be if
History of coronary artery bypass graft (CABG).
Moderate to severe renal dysfunction.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during screening.
History of hemorrhagic stroke.
History of major bleeding disorder.
Planned cardiac surgery or arterial revascularization.
Severe heart failure.
Current, recent, or planned lipoprotein apheresis.
Previously received ribonucleic acid therapy specifically targeting Lp(a).
Clareo Health | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
